Related Experiment Video
Updated: Feb 15, 2026

Sublingual Immunotherapy as an Alternative to Induce Protection Against Acute Respiratory Infections
Published on: August 30, 2014
Single vs multiallergen sublingual immunotherapy in the polysensitized patient: a pilot study
Alexandra Shams Ortiz1, K Christopher McMains1, Adrienne M Laury1
1Department of Otolaryngology, San Antonio Military Medical Center, Fort Sam Houston, TX.
Sublingual immunotherapy (SLIT) effectively improves allergy symptoms for polysensitized patients, regardless of whether single, few, or multiple allergens are used. This study found no significant difference in efficacy based on the number of allergens in the SLIT regimen.
Area of Science:
- Allergy and Immunology
- Immunotherapy Research
- Clinical Trials
Background:
- Sublingual immunotherapy (SLIT) is a safe and effective treatment for atopic patients.
- The optimal number of allergens for SLIT in polysensitized patients remains unclear.
- Current practices for allergen inclusion in SLIT vary widely.
Purpose of the Study:
- To compare the efficacy of single-allergen SLIT versus pauci-allergen and multi-allergen SLIT in polysensitized patients.
- To evaluate the impact of the number of allergens on SLIT treatment outcomes.
- To provide evidence-based guidance for SLIT regimen design in complex allergy cases.
Main Methods:
- A randomized, blinded study involving 16 subjects sensitized to 6+ allergens.
- Subjects received SLIT with 1 (single), 3 (pauci), or all (multi) sensitized allergens.
- Outcomes measured included allergy medication use, Rhinoconjunctivitis Symptom Score (RCSS), and mini-Rhinoconjuncitivitis Quality of Life Questionnaire (m-RQLQ) over 9 months.
Main Results:
- Significant decreases in RCSS and m-RQLQ scores were observed in all treatment groups.
- No significant reduction in daily allergy medication use was found across groups.
- No significant differences in efficacy were noted based on the number of allergens included in the SLIT.
Conclusions:
- Single-antigen, pauci-antigen, and multiantigen aqueous SLIT all significantly improve allergy symptoms.
- The number of allergens used in SLIT does not appear to affect treatment efficacy in polysensitized individuals.
- SLIT is a viable treatment option for polysensitized patients, with comparable outcomes regardless of allergen load.
Related Concept Videos
Pilot and Numeric Relaying
Tumor Immunotherapy
Bioavailability Study Design: Single Versus Multiple Dose Studies
Bioavailability Study Design: Healthy Subjects Versus Patients
Patient-centered Care
Drug Dosing: Geriatric Patients

